

A-1331852

Catalog No: tcsc5565



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1430844-80-6

Formula:

$C_{38}H_{38}N_6O_3S$

Pathway:

Apoptosis

Target:

Bcl-2 Family

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (75.89 mM); H₂O :

Observed Molecular Weight:

658.81


Product Description

A-1331852 is an orally available **BCL-XL** selective inhibitor with a **K_i** of less than 10 pM.

IC₅₀ & Target: K_i: less than 10 pM (BCL-XL)^[1]

In Vitro: A-1331852 selectively disrupts BCL-XL-BIM complexes and induces the hallmarks of apoptosis in BCL-XL-dependent Molt-4 cells with IC₅₀s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC₅₀ values of 3, 7, 80, 120 and 100 nM^[1].

In Vivo: A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!